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Background: Cancer-related fatigue (CRF) is one of the most common and distressing side effects of cancer and its
treatment. During and after radiotherapy breast cancer patients often suffer from CRF which frequently impairs
quality of life (QoL). Despite the high prevalence of CRF in breast cancer patients and the severe impact on the
physical and emotional well-being, effective treatment methods are scarce.
Physical activity for breast cancer patients has been reported to decrease fatigue, to improve emotional well-being
and to increase physical strength. The pathophysiological and molecular mechanisms of CRF and the molecular-
biologic changes induced by exercise, however, are poorly understood.
In the BEST trial we aim to assess the effects of resistance training on fatigue, QoL and physical fitness as well as on
molecular, immunological and inflammatory changes in breast cancer patients during adjuvant radiotherapy.
Methods/design: The BEST study is a prospective randomized, controlled intervention trial investigating the effects
of a 12-week supervised progressive resistance training compared to a 12-week supervised muscle relaxation
training in 160 patients with breast cancer undergoing adjuvant radiotherapy. To determine the effect of exercise
itself beyond potential psychosocial group effects, patients in the control group perform a group-based progressive
muscle relaxation training. Main inclusion criterion is histologically confirmed breast cancer stage I-III after
lumpectomy or mastectomy with indication for adjuvant radiotherapy. Main exclusion criteria are acute infectious
diseases, severe neurological, musculosceletal or cardiorespiratory disorders. The primary endpoint is cancer-related
fatigue; secondary endpoints include immunological and inflammatory parameters analyzed in peripheral blood,
saliva and urine. In addition, QoL, depression, physical performance and cognitive capacity will be assessed.
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Discussion: The BEST study is the first randomized controlled trial comparing progressive resistance training with
muscle relaxation training in breast cancer patients during adjuvant radiotherapy. Based on the analysis of
physiological, immunological and inflammatory parameters it will contribute to a better understanding of the
physiological and psychosocial effects and the biological mechanisms of resistance training. The ultimate goal is the
implementation of optimized intervention programs to reduce fatigue, improve quality of life and potentially the
prognosis after breast cancer.
Trial registration: ClinicalTrials.gov NCT01468766Background
Adjuvant radiotherapy is used in more than 90% of all
breast cancer patients. It is usually given after breast-
conserving surgery and may be given after a mastectomy
if patients are at high risk of recurrence. After breast-
conserving surgery, adjuvant radiotherapy to the in-
volved breast significantly increases the progression free
survival and reduces the breast cancer death rate by
about a sixth [1]. While radiotherapy reduces breast can-
cer recurrence and mortality it may also be associated
with acute and long term toxicity. The most frequently
reported adverse effect is cancer-related fatigue (CRF), a
common early and also a late side-effect of irradiation,
reported in up to 80% of patients during radiotherapy
[2-6]. As per definition, CRF is a persistent, subjective
sense of tiredness related to cancer or cancer treatment
that interferes with usual functioning and that is usually
not relieved with rest and is not related to an excessive
amount of activity. Over the course of radiotherapy the
proportion of patients with CRF and the severity of CRF
gradually tends to intensify. CRF peaks at the end of
radiotherapy and in about 30% of patients it may persist
even for many months post-treatment [3,6-8]. Despite
the high prevalence and the severe impact of CRF on
the physical and emotional well-being and the quality of
life (QoL), the aetiology of this common symptom and
its correlates are poorly understood and effective treat-
ment methods are scarce. Several interventions have
been tested in the management of CRF. Although an
optimal method has not yet been established, some prom-
ising results have been reported with relaxation the-
rapy, group psychotherapy, physical exercise and sleep.
The National Comprehensive Cancer Network (NCCN)
guidelines recommend treatment for pain, emotional
distress, and anemia as well as optimizing treatment for
sleep dysfunction, nutritional deficiency or imbalance,
and comorbidities [9]. Initially tested pharmaceuticals
have shown severe adverse effects (e.g. erythropoietin),
or did not show efficacy in phase III studies (e.g. me-
thylphenidate) [10]. A Cochrane review from 2008, a
roundtable of the American College of Sports Medicine
published in 2010, and a recent comprehensive meta-analysis on published reports of 44 exercise studies with
the endpoint CRF concluded that exercise may be an ef-
fective treatment method for CRF, but that the evidence
is not yet convincing [11-13]. The meta-analysis pub-
lished by Brown et al, however, was based on summary
data from actual research papers but did not analyze in-
dividual patient data [13]. However, most of the previ-
ously reported controlled intervention trials used “usual
care” as comparison group. Therefore, it is unclear to
what extent the observed effects may be based on the
physical exercise itself, or rather on psychosocial factors
related to the group support or the attention by the
trainer. Thus, methodologically correct studies are war-
ranted to better define the causes, the optimal preven-
tion and the management of CRF.
Furthermore, it is still unclear what type of exercise, i.
e. aerobic or resistance training, and what point in time,
i.e. during or after cancer treatment, is most effective.
The majority of previous controlled trials investiga-
ted aerobic exercise. Resistance training has been lit-
tle examined and even fewer studies tested resistance
interventions performed during adjuvant radiotherapy
[11,14,15].
The molecular mechanisms of fatigue as well as the
molecular changes induced by exercise are still largely
unknown. Inflammation and other immunomodulatory
mechanisms are supposed to be of importance for the
outcome and prognosis of cancer. Irradiation can cause
a weakening of the immune system but may also induce
severe systemic inflammation in the short, and perhaps
even long-term [16-18]. Several large trials among
healthy individuals or cancer survivors reported that ex-
ercise including resistance training can lead to a reduc-
tion of markers of inflammation such as C-reactive
protein (CRP) [19-24]. These results suggest that anti-
inflammatory factors might mediate the beneficial ef-
fects of resistance training on fatigue during adjuvant
radiotherapy.
In addition, key immunomodulators like tumor-specific
CD4+CD25+ forkhead transcription factor Fox P3 (FoxP3)
positive regulatory T lymphocytes also known as regula-
tory T-cells (Tregs) are spontaneously induced by many
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positive Tregs in peripheral blood and tumor have been
reported in patients with various types of cancer includ-
ing ovarian cancer [28,29], breast cancer [30] and other
tumors [27]. A lack of FoxP3-expressing T-cells can
lead to autoimmune disease, whereas an abundance of
FoxP3-expressing regulatory T-cells can result in im-
mune deficiency [25]. Increased numbers of Tregs have
been associated with a worse breast cancer prognosis
[31-33], For example, Bates et al. reported that high
numbers of FoxP3-positive Tregs were identified in pa-
tients with ductal carcinoma in situ at increased risk of
relapse, and in patients with invasive breast tumors with
both shorter relapse-free and overall survival [30]. In
addition to their potential value in predicting disease
progression and relapse, FoxP3-positive Tregs have re-
cently been reported to be a marker for the monitoring
of therapeutic response. Merlo et al suggest that FoxP3
itself is expressed in breast cancer cells, and that the ex-
pression level is associated with patient survival [34].
Whereas increased numbers of Tregs have been corre-
lated with a worse breast cancer prognosis [30-34], ex-
ercise has been correlated with a trend towards a better
prognosis [35]. This raises the question whether exer-
cise might have an effect on the level of Tregs and
whether they might be one of the molecular mediators
of the beneficial effects of exercise seen in cancer pa-
tients. To date, however, immunological and molecular
factors have only been minimally studied with respect
to fatigue, and the effect of resistance training during
radiotherapy on the Treg level in breast cancer patients
is unclear.
The aetiology of fatigue during radiotherapy is also
not well defined. The course and severity differ between
radiotherapy- and chemotherapy-induced fatigue, which
suggest different pathways [36]. Overall, methodologic-
ally optimized randomized controlled clinical trials and a
better understanding of the pathophysiology and the
molecular mechanisms of fatigue induced by radiother-
apy as well as the mode of action of resistance training
are important for evidence-based exercise recommenda-
tions for breast cancer patients during treatment.... -1 0 1 2 3 4 5 6 7 8 9 10Week
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Figure 1 Study design of the BEST study.The BEST trial is a prospective, randomized controlled
intervention study in breast cancer patients during adju-
vant radiotherapy exploring the effects of a 12-week su-
pervised progressive resistance training on CRF, QoL,
depression, as well as muscular strength, cardiorespiratory
fitness, and body composition. Moreover, pathophysio-
logical, molecular and immunological mechanisms of fa-
tigue and exercise will be analyzed.
To determine the specific effects of the exercise pro-
gram itself beyond potential psychosocial effects related
to a supervised group-based training, patients in the
control group receive a comparable training schedule,
yet with group-based progressive muscle relaxation (also




The BEST study (“Bewegung und Entspannung für
Brustkrebspatientinnen unter Strahlentherapie”; English:
“exercise and relaxation for breast cancer patients during
radiotherapy”) is a prospective, randomized, controlled
clinical intervention trial in stage I-III female breast can-
cer patients during adjuvant radiotherapy. Women have
to provide written informed consent prior to partici-
pation in the study. After baseline assessments, par-
ticipants are randomized to a supervised progressive
resistance training or a supervised relaxation program
over a period of 12 weeks (see Figure 1). Both interven-
tions are administered group-based. Endpoints are
assessed within 21 days before radiotherapy (baseline,
T0), after the end of radiotherapy (week 7, T1), after
the end of the intervention (week 13, T2), and 2, 6, and
12 months post-intervention (T3, T4, T5) (see Figure 2).
Blood (serum, plasma, peripheral blood mononuclear
cells (PBMCs)), urine, and saliva (5 samples over one
day) are collected at T0, T1, and T2.
To enhance the participation rate and maintain high
compliance to the intervention scheme, participants are
offered to train for another 12 weeks in the program of
their choice after completion of the 12-weeks random-
ized intervention period. The intervention programs and11 12 13 14 15 16 17 18 19 20 ... 38 ... 64
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Figure 2 Study flow of the BEST study.
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from a randomized controlled trial with breast cancer
patients during chemotherapy conducted by our group
(BEATE study) [38].
The BEST study has been approved by the ethics com-
mittee of the University of Heidelberg in December 2010
(number S-447/2010) and is registered at ClinicalTrials.
gov (NCT01468766).Objectives
The primary objective of the BEST trial is to determine
the effect of resistance training on fatigue compared to a
relaxation control group among breast cancer patients
during adjuvant radiotherapy.
Secondary objectives are to estimate the effects of the
resistance training on quality of life, depression, cogni-
tive function, and early and late radiotoxicity, as well as
on physical fitness, including muscle strength, cardio-
respiratory fitness, flexibility, and body composition. The
effects of the resistance training on immunologic and in-
flammatory parameters and other biomarkers relevant to
cancer prognosis will also be tested. Further, hypothesized
biological mediators of physical activity and cancer-related
fatigue will be explored and the relationships between
cancer-related fatigue, physical fitness, and biomarkers
of stress, inflammation, and immune function will be
modelled. Safety and feasibility of progressive resistance
training during radiotherapy will be evaluated, and the
sustainability of the effects will be assessed.
Patient selection
The BEST study includes women with histologically con-
firmed primary breast cancer who are scheduled for ad-
juvant radiotherapy at the University of Heidelberg
Medical Center and who do not have any contraindica-
tions for a progressive resistance training. Inclusion and
exclusion criteria are provided in Table 1.
Recruitment and randomization
All eligible breast cancer patients scheduled for adjuvant
radiotherapy at the University of Heidelberg Medical
Center are briefly informed about the BEST study during
the therapy counselling visit (about 1-2 weeks before
start of radiation). If interested, patients are then in-
formed in detail by the BEST study physician and inclu-
sion and exclusion criteria are verified. For each patient
recruited into the study, written informed consent is es-
sential prior to inclusion into the study after extensive
information about the intent of the study, the study regi-
men, potential associated risks and side effects. The in-
vestigator will not undertake any diagnostic measures
specifically required for the clinical trial until valid con-
sent has been obtained. Upon written informed consent,
the patient is scheduled for the baseline visit, which
should be within 21 days prior to the start of radiation.
After completion of the baseline assessment and if
the testing procedure does not indicate cardiovascular,
respiratory or neurological problems that may contrain-
dicate resistance training, the participant is randomly allo-
cated to one of the two intervention groups. Allocation is
done by the biometrician based on a predetermined list
generated with a blocked randomization SAS procedure
with a fixed block size, stratified by age (< 50 / ≥ 50 years
Table 1 Inclusion and exclusion criteria of the BEST study
Inclusion criteria Exclusion criteria
• Female patients with histologically confirmed primary breast cancer, stage I-III after
lumpectomy or mastectomy scheduled for adjuvant radiotherapy at the University of
Heidelberg Medical Center
• Acute infectious disease
• Inability to walk or stand
• Severe neurological deficiencies
• Age ≥18 years of age • Severe cardiac or cardiovascular disease
• BMI ≥18 kg/m2 • Severe respiratory insufficiency
• Ability to understand and follow the study protocol • Severe renal failure
• Willingness to come to the Heidelberg exercise facilities and adhere to study protocol • Other concurrent malignant disease (except carcinoma in
situ of skin or cervix)
• Written informed consent • Substance abuse (potentially leading to non-compliance)
• Participation in systematic intense resistance or aerobic
training (at least 1 h twice per week)
• Previous participation in another exercise intervention trial
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Stratification is used in the randomization process, as we
anticipate these variables to have major influence on the
outcome. To prevent possible bias, study personnel in-
volved in the recruitment and the baseline assessment do
not have access to the randomization lists and are not
aware of the block size. Conversely, the biometrician does
not have influence on the recruitment procedure.
Recruitment of n=160 patients started in February
2011 and was completed in March 2013.
Interventions
The begin of the training is the day of the first radiother-
apy treatment. Patients participate in the intervention or
control program for 60 minutes, twice weekly for 12 -
weeks. Participants train together with other cancer pa-
tients under supervision and guidance of experienced
therapists. At days of radiation, participants frequently
train directly before or after radiation due to logistic rea-
sons. The physical status and well-being prior to and
after a training session are recorded by the participant.
The trainer documents attendance of each participant at
each session. Similarly, if sessions have been missed, rea-
sons are documented. In addition, for the resistance
training individual weights and number of repetitions
performed are documented.
Exercise intervention
Sessions are comprised of machine-based resistance ex-
ercise located at the training center of the Institute for
Sports and Sports Sciences in Heidelberg. The hypothet-
ical one-repetition maxima (1-RM) according to the
Brzycki-Method [39] is defined for each exercise task in
the first training session. The resistance training proto-
col complies with the American College of Sports Medi-
cine (ACSM) exercise guidelines for cancer survivors
[12] and with ACSM recommendations for progressiveresistance training for novice weightlifters and older
adults. This protocol includes one to three sets at a
weight that can be handled for 8 to 12 repetitions (ap-
proximately 60–80% of 1-RM) [40,41] with a resting
time of one minute between the sets. A complete session
takes approximately 60 minutes and includes eight dif-
ferent types of exercises for major upper and lower
muscle groups: 1) leg extension; 2) leg curl; 3) leg press;
4) shoulder internal and external rotation; 5) seated row;
6) latissimus pull down; 7) shoulder flexion and exten-
sion; and 8) butterfly and butterfly reverse. Training is
progressive in terms of weight increase to the next ma-
chine weight level (at least by 5%) after successfully
completing 3 sets of an exercise with 12 repetitions in
three consecutive exercise sessions.
Relaxation intervention
Similar to the resistance training the relaxation interven-
tion is performed for 60 minutes, twice weekly for 12 -
weeks in the exercise facility of the National Center for
Tumor Diseases (NCT) in Heidelberg. It is based on
the progressive muscle relaxation method according to
Jacobson and does not include any aerobic or muscle
strengthening components [37].
Outcome measures
The outcome measures used in the BEST study are sum-
marized in Table 2.
Fatigue
The primary endpoint is change of fatigue from baseline
to week 13. Fatigue is assessed with the Fatigue Assess-
ment Questionnaire (FAQ) which is a 20-item, multidi-
mensional self-assessment questionnaire that has been
validated for a German-speaking population [42]. It covers
the physical, affective, and cognitive fatigue dimensions,
and includes one item on sleep disorders. Scores are
Table 2 Assessments and instruments used in the BEST study
Outcomes Instrument T0 T1 T2 T3 T4 T5
Primary endpoint
Fatigue Fatigue assessment questionnaire (FAQ) X X X X X X
Secondary endpoints
Quality of life EORTC QLQ30 / BR-23 questionnaire X X X X X X
Depression Center for Epidemiological Studies Depression Scale (CES-D) X X X X X X
Cognitive function Trail-making-test X X X X X
Body composition Bioimpedance analysis, weight, height, waist and hip circumference X X X X X
Muscle strength Isometric and isokinetic strength of representative muscle groups for upper and lower
extremity measured at the IsoMed2000W
X X X X
Cardio-respiratory fitness Spiroergometry (VO2peak) X X X X
Flexibility Range of motion measured at the IsoMed2000W X X X X
Radiotoxicity Acute radiation dermatitis, LENT-SOMA classification for late effects, ECOG performance
status, hemoglobin , and thrombocytes at end of radiotherapy
X X
Circulating immune cells Analyzed in peripheral blood X X X
Biomarkers of inflammation
and oxidative stress
Analyzed in peripheral blood and urine X X X
Salivary cortisol Saliva collected at five different time points during a day X X X
Sample collection data Date and time of collection, as well as time since last food or fluid intake, vigorous physical
activity (during last 12 h), NSAID intake (during last 12 h), smoking (during last 24 h),
caffeine intake (during last 6 h), alcohol intake (last 48 h), acute infections, and sleep quality




Number of participants with lymphedema, pain, nausea, dyspnea, or tachycardia during the
intervention phase
at each training session
Others
Socio-demographic factors Recording of date of birth, education, occupation, socio-familial situation, smoking, alcohol
consumption
X
Breast cancer characteristics Family history, TNM status, grading, ER/PR status, HER2-score, p53, bcl-2, Ki-67, X
Medical history Recording of pre-existing diseases and of allergies X
Treatment data Pre-treatment: ECOG at diagnosis, date and type of breast surgery, affected lymph nodes,
(neo-) adjuvant chemotherapy (type, last infusion), hormone therapy
X
Radiation: technique (3D, IMRT), type and dose, start and stop date, interruptions
Concomitant medication Recorded at each visit on a medication log form X X X
Physical activity history Physical activity in adolescence, pre-diagnosis, during, and after intervention is recorded,
including walking, cycling, and sports
X X X X X
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2=quite a bit, 3=very much) of the appropriate items.
Reference values of the FAQ scores are available from a
representative sample of the German population including
1,340 women stratified by age [43].
Quality of life (QoL)
QoL is assessed with the validated 30-item self-assessment
questionnaire of the European Organisation for Research
and Treatment of Cancer (EORTC QLQ-C30, version
3.0). It includes five multi-item functional scales (phy-
sical, role, emotional, cognitive, and social function), three
multi-item symptom scales (fatigue, pain, nausea/vomit-
ing), and six single items assessing further symptoms(dyspnea, insomnia, appetite loss, constipation, diarrhea)
and financial difficulties [44]. In addition, the 23-item
breast cancer specific module (EORTC QLQ-BR23) is ap-
plied, assessing common problems of breast cancer pa-
tients, e.g. with the affected breast or arm. Scores are
derived according to the EORTC scoring manual [45].
Reference values are available from the EORTC reference
manual [46] and from a sample of the general German
population stratified by gender and age [47]. Further,
evidence-based guidelines for the interpretation of the
clinical relevance of changes in the different EORTC
QLQ-C30 subscales were recently published [48], categor-
izing differences between scores in trivial, small, medium,
or large effect sizes.
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Depressive symptoms are assessed with the 20-item
Center for Epidemiological Studies Depression Scale
(CES-D). The CES-D scale is a widely used validated
self-report instrument to measure current depressive
symptomatology and to identify possible cases of depres-
sive disorders, both in the general population and in pa-
tients with cancer [49].
Cognitive function
Cognitive function (concentration, cognitive flexibility) is
estimated with the trail-making-test. This is a standard-
ized, reliable and valid measure used in neuropsycho-
logical diagnostics [50,51]. The test measures the time
needed by the participant to connect numbers and let-
ters on a sheet of paper in a logical sequence.
Radiotoxicity
Onset and duration of acute radiodermatitis is recorded
due to the NCI-CTCAE criteria version 4.02. The “Late
Effects of Normal Tissue – Subjective, Objective, Man-
agement, and Analytic scales” (LENT-SOMA) are ap-
plied at week 13 asking for ulcerations, telangiectasias,
palpatory changes, retraction, atrophy, edema in the
breast, lymph edema, and fibrosis [52]. The LENT-
SOMA allows the quantification of late effects on nor-
mal tissue.
Physical fitness
All fitness measures are performed by trained study
personnel at the Division of Preventive Oncology at the
NCT.
Muscle strength is assessed by measuring isometric
(4 positions) and isokinetic (2 angular velocities) muscle
capacity with the IsoMed 2000W diagnostic module (iso-
kinetic evaluation and training machine, D&R Ferstl
GmbH, Hemau, Germany). The protocol includes testing
of representative muscle groups for upper (shoulder ro-
tators) and lower extremity (knee extensors and flexors).
Reliability and validity of isokinetic dynamometer ma-
chines have been reported in several studies, with coeffi-
cients of variation below 10% [53-55].
Endurance performance (VO2peak) is measured on a bi-
cycle ergometer (Ergostik, Geratherm Respiratory GmbH,
Bad Kissingen, Germany) by performing a symptom-
limited test with a step protocol (starting at 50 watt with
steps of 25 watts every 2 minutes). The criteria of exhaus-
tion is defined as achieved estimated maximum heart rate,
plateau in VO2 and RQ >1.1. VO2peak is defined as
highest 30-second average during the test. Peak workload,
peak oxygen uptake and oxygen uptake at ventilatory
threshold are taken for analysis. Cardiorespiratory exercise
testing is well established in cancer patients and recom-
mendations for testing procedures as well as safetyguidelines in clinical trials with cancer populations have
been defined [56]. The procedure is also used to exclude
exercise-contraindicating cardiac impairments.
Body composition of the participants is measured
with bioelectrical impedance analysis (BIA, Akern Srl,
Pontassieve, Italy). This is a quick and non-invasive met-
hod, which determines the electrical impedance, or op-
position to the flow of an electric current through body
tissues to calculate an estimate of total body water, fat-
free body mass and body fat [57]. BIA gives reliable
measurements of body composition with minimal intra-
and inter-observer variability in healthy volunteers [58].
In cancer patients during therapy, derived variables
need to be interpreted with caution, e.g. due to potential
lymphedema. In addition, algorithms used to calculate
%fat mass might lead to biased values [59]. Thus, our
focus will be on inter-individual changes with respect to
the phase angle (reactance and resistance) during the
intervention period rather than on absolute values or
computed values for different compartments. In ad-
dition, body weight in light clothing, height, hip- and
waist circumference are measured.
Biospecimen collection and biomarkers
Serum, plasma, and PBMCs are derived from whole per-
ipheral blood samples, processed within 2 hours after
taking the blood sample and stored at -80°C or cryo-
preserved in liquid nitrogen (PBMCs) for analyses of
biomarkers after completion of the last study participant.
Only CRP is directly analysed with nephelometry within
the clinical routine lab.
Urine samples are collected for analyses of biomarkers of
oxidative stress, i.e. urinary F2-isoprostane and 8-oxo-dG
measured by chromatography-based methodology.
Saliva samples are collected with salivettes by the par-
ticipants at 5 specific time points during a day (at wak-
ing, +0.5 h, noon, 5 pm, 10 pm/bed time) for analyses of
diurnal cortisol slopes and cortisol morning peaks after
study completion.
Immunological factors are assessed in fresh blood, in-
cluding the quantity of FoxP3+ CD25+ regulatory T-cells
and circulating lymphocytes subpopulations. In addition,
in a subpopulation of n=40 participants (20 of each inter-
vention arm) the specificity of FoxP3+ CD25+ regulatory
T-cells is measured.
Safety issues
Potential adverse effects (e.g. lymphedema, pain, muscle
soreness, nausea, dyspnea, tachycardia) are recorded by
the participants at each training session by standard-
ized questionnaires throughout the intervention period.
Adverse events reported spontaneously by the patient or
observed by physiotherapists, study nurse or physicians
are recorded, e.g. sports accidents or injuries.
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The primary aim is to compare changes on the overall fa-
tigue scale from baseline to week 13 between the exercise
and relaxation group. To detect a mean standardized ef-
fect size of 0.5 with a two-sided t-test with significance
level 0.05 with a power of 80% a sample size of 80 breast
cancer patients per arm is needed, 160 women in total, as-
suming a maximal drop-out rate of 20%. However, adjust-
ment for the pre-intervention fatigue value in the
regression models on post-intervention fatigue will lead to
an improved power above 80% depending on the correl-
ation between the pre- and post-intervention values [60].
This sample is also large enough to detect medium
sized clinically relevant intervention effects on the sec-
ondary outcome EORTC QLQ-C30 subscales. Evidence-
based guidelines for the interpretation of the clinical
relevance of changes in the different EORTC QLQ-C30
subscales were recently published [48], categorizing dif-
ference between scores (on the 0-100 points scale) in
trivial, small, medium, or large effect sizes. For example,
effects are considered as medium size for differences of
19-29 in role function, differences of 14-22 in physical
function, 11-15 in social function, 9-14 in cognitive
function, and 13-19 for fatigue.
Data analysis
The main intervention effect will be assessed on the
basis of a comparison between exercisers and controls as
defined at randomization, regardless of exercise adher-
ence, i.e. according to the intent-to-treat principle. The
differences in fatigue between groups will be assessed
with a generalized estimating equation (GEE), which ac-
counts for repeated observations on the same subjects
over time. This method provides the most efficient esti-
mate for the intervention effect in pretest-posttest trials
[61]. Normality assumptions will be checked and data if
necessary transformed. Imputation-based sensitivity ana-
lyses will be conducted to examine the potential effect of
missing data on the results.
Similar analyses as for fatigue will also be performed
for the secondary endpoints. In addition, analyses will
be performed stratified by pre-treatment (e.g. neoadju-
vant, adjuvant or no previous chemotherapy), to
evaluate potential differential effects of the exercise
intervention by pre-treatment. Further, subgroup effects
of resistance training versus relaxation controls will be
explored stratified by training adherence, changes in
muscle strength, cardiorespiratory fitness, and body
composition. Correlation analyses will be used to exam-
ine the relationship between changes of the various
measured endpoints. Regression analyses regarding the
repeated measurement design (T0, T1, T2, T3, T4, T5)
will be applied to investigate the association between
therapy modalities, cardiorespiratory fitness, musclestrength, and body composition and the different fa-
tigue as well as QoL dimensions. The influence of other
potential confounding factors, such as age, smoking,
clinicopathologic characteristics, and comorbidities will
be explored and accounted for in the analyses.
In addition, change in physical activity behavior post
intervention will be explored for the follow-up time
points using descriptive analysis.
Discussion
The BEST study will add to current knowledge about exer-
cise in breast cancer patients with respect to several novel
aspects being tested: (1) Exercise performed in parallel to
radiotherapy; (2) progressive resistance training; (3) exer-
cise effect beyond psychosocial training effects; (4) effects
on immune function, and (5) sustainability and long-term
effects of a 12-week exercise intervention.
Among breast cancer patients receiving radiotherapy
the most frequently reported side effect is fatigue. As
about 72.000 women in Germany are newly diagnosed
with breast cancer each year [62], the majority receiving
radiotherapy, this radiation-related fatigue is a substan-
tial health problem. Exercise may be an effective treat-
ment against fatigue. Thus, it is surprising that exercise
during radiotherapy has been minimally investigated in
breast cancer patients so far. To our knowledge, only
five randomized exercise trials included breast cancer
patients during adjuvant radiotherapy [63-67]. Three
of these studies included also patients during other
adjuvant treatments (chemotherapy, hormone therapy)
[64,66,67] and one was a pilot study including also pros-
tate cancer patients [65], leaving only one exercise study
with only breast cancer patients during adjuvant radio-
therapy but with a small sample size of only n=46 [63].
Radiation can be muscle damaging (myotoxic), result-
ing in significant reductions in skeletal muscle mass and
function [68]. Resistance training can counteract this
muscle degradation. The negative influence of cancer
therapy is a major rationale to investigate the effect of
resistance exercise during adjuvant radiotherapy, as
training in parallel to adjuvant treatment might prevent
or mitigate treatment side effects such as fatigue.
Previous randomized exercise trials mostly investigated
aerobic exercise, but benefits of resistance training in
cancer patients and survivors on quality of life and fa-
tigue have also been reported [15,69-71]. To our know-
ledge, only seven studies investigated pure resistance
training in cancer patients and survivors [69,72-77].
Among those studies, two had insufficient power (n=22
and 38) [76,77] and of the others only three focused
on breast cancer patients [69,72,75]. However, no ran-
domized controlled trial investigated progressive resist-
ance training in breast cancer patients during adjuvant
radiotherapy.
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the control group, i.e. of a standardized relaxation train-
ing without any aerobic or resistance exercise com-
ponents, but which reflects the training schedule and
psychosocial conditions of the exercise intervention.
Positive psychosocial “side effects” of group-based exer-
cise training have been observed [78], which potentially
can contribute to a lower perception of fatigue and
higher QoL, in addition to physiological effects of the
exercise on fatigue. Thus, the BEST design enables us
to discern the “pure” physiological effects of exercise
beyond potential psychosocial effects of a group-based
training, which are related to social interactions, group
support, improved self-efficacy, or attention by the
trainer. Psychosocial and behavioural interventions have
also shown some beneficial effects regarding fatigue and
QoL [79,80]. Thus, it is still unclear, to what extent the
observed benefits of exercise interventions are really
caused by physical training, because previous studies
have commonly used a “usual care” control group.
Further, the pathophysiology of fatigue and the mode
of action of exercise on its prevention and treatment are
not well understood. Our trial enables investigation of
the effects of resistance training on immunologic param-
eters as well as on biomarkers of inflammation, oxidative
stress, and diurnal cortisol slopes. While the interven-
tion effect on fatigue and potential underlying biological
mediators is one focus of the trial, another focus is the
examination of the effects of resistance exercise on prog-
nostic factors and health-relevant biomarkers. Especially
regulatory T-cells will be investigated in detail, as those
have been found to be associated with prognosis in
breast cancer patients [31-33].
Finally, in case of the detection of beneficial effects
during or at the end of an exercise intervention, it is of
interest whether those benefits sustain over a longer
period of time. To-date, data on the sustainability of ex-
ercise interventions is limited. Therefore, we follow the
BEST participants over one year post-intervention and
assess at 3 post-intervention time-points fatigue, QoL,
physical fitness, and their physical activity behavior.
In summary, the BEST study shall contribute to a bet-
ter understanding of the physiological and psychological
effects of resistance training and their biological and
immunological mechanisms in breast cancer patients
during adjuvant radiotherapy. The ultimate goal is the
implementation of an optimized intervention program
to reduce fatigue and improve quality of life and poten-
tially the prognosis after breast cancer.
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